Monash IVF Group (MVF) Guidance summary
Event summary combining transcript, slides, and related documents.
Guidance summary
6 Jun, 2025Opening remarks and agenda
Provided an update on anticipated Underlying NPAT for the year ending 30 June 2025, revising previous guidance.
Guidance on key objectives
FY25 Underlying Group NPAT is now expected to be approximately $27.5m, down from prior guidance of $30.0m–$31.0m.
Non-regular items for FY25 will include costs related to the Brisbane incident, legal, and advisory expenses.
Market trends and strategic opportunities
Softer market and operating conditions in March and April 2025 impacted performance across all geographic markets.
May 2025 showed improved operating conditions, but not enough to offset earlier months' impact.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Monash IVF Group
- Underlying NPAT dropped 34% to AUD 10.4M as domestic IVF softened, but international and genetics grew.MVF
H1 202626 Feb 2026 - Underlying profit and revenue grew strongly, with robust outlook despite one-off legal impact.MVFH2 202423 Jan 2026
- Record profit, global expansion, and Vision 2026 defined a year of growth amid class action impact.MVFAGM 202412 Jan 2026
- Record revenue and profit growth, stable margins, and FY25 NPAT guidance above prior year.MVFH1 202524 Dec 2025
- FY2025 met guidance with solid earnings; FY2026 reset expected before growth resumes.MVFH2 202523 Nov 2025
- FY2025 saw revenue and EBITDA growth, lower NPAT, and no dividend, with renewal and digital focus.MVFAGM 202520 Nov 2025